# Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

> **NCT00258440** · NA · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- Anemia
- Fatigue
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** Weekly procrit dosing
- **DRUG:** Interval Dosing

## Key facts

- **NCT ID:** NCT00258440
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Sponsor discontinued funding of the study
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258440, "Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00258440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*